Skip to content
Open access

Astilbin Ameliorates Atopic Dermatitis via Modulation of miR-31-5p

Oct 2026 · Pharmacognosy Magazine · 0 citations · 36 references

TL;DR

AL significantly improves AD, potentially by inhibiting miR-31-5p expression to reduce inflammatory responses and improve keratinocyte function, and provides a novel therapeutic target for AD.

Abstract

Previous studies have reported the potential role of astilbin (AL) in skin lesions and the abnormal expression of miR-31-5p in the skin of patients with atopic dermatitis (AD). To elucidate the efficacy of AL in improving AD and to determine whether its molecular mechanism is associated with miR-31-5p. Serum miR-31-5p levels were measured via reverse transcription quantitative polymerase chain reaction (RT-qPCR) in 32 AD patients and 25 healthy controls. A 2,4-dinitrofluorobenzene (DNFB)-induced AD mice model was established to evaluate AL’s therapeutic effects using dermatitis/erythema scores, itching behavior, and serum immunoglobulin E (IgE)/inflammatory factor levels measured by enzyme-linked immunosorbent assay (ELISA). An in vitro AD model using tumor necrosis factor-α/interferon-γ (TNF-α/IFN-γ)-stimulated human keratinocyte (HaCaT) cells was established. The impact of AL on cell viability and inflammatory factors was analyzed using cell counting kit-8 (CCK-8) and ELISA. Rescue experiments assessed the miR-31-5p regulatory mechanism. Serum miR-31-5p was significantly upregulated in AD patients and model mice. AL alleviated AD symptoms dose-dependently by reducing serum IgE and inflammatory cytokines (TNF-α, IL-4 (interleukin-4), IL-6 (interleukin-6), IL-1β (interleukin-1β)). AL suppressed TNF-α/IFN-γ-induced miR-31-5p overexpression in HaCaT cells, improved cell viability, and reduced inflammatory factor secretion. These effects were partially reversed by a miR-31-5p mimic. AL significantly improves AD, potentially by inhibiting miR-31-5p expression to reduce inflammatory responses and improve keratinocyte function. This study reveals a pharmacological role for AL and provides a novel therapeutic target for AD.

Read PDF

Similar papers

Open access Aug 2026

Tetrandrine exerts anti-inflammatory and HaCaT cell-protective effects in atopic dermatitis by targeting miR-494-3p

The active ingredient, Tetrandrine (TET), derived from the Nidus Vespae, exhibits diverse pharmacological activities, including anti—inflammatory, antioxidant, and immunomodulatory effects. To demonstrate the effectiveness of TET in the treatment of atopic dermatitis and its underlying mechanism of action. The atopic d...

Jun-Ling Zhu, Qi-Mei Xie, Cheng-Wu Kuang et al. · 0 citations
Aug 2026

LncRNA NONMMUT051252 promotes atopic dermatitis via the miR-141-5p/USP14/cGAS-STING axis and ferroptosis.

These findings identify a previously unrecognized lncRNA 051252/miR-141-5p/USP14/cGAS-STING signaling axis that drives inflammatory responses and ferroptosis in AD, providing new mechanistic insights into disease pathogenesis and highlighting potential therapeutic targets.

Yue Du, Shan Jin, Ke-Xin Xu et al. · 1 citation
Open access Sep 2026

Helichrysum Essential Oil Ameliorates Atopic Dermatitis by Suppressing the NLRP3 Inflammasome and Restoring Epidermal Barrier Integrity

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by immune dysregulation and epidermal barrier dysfunction. The essential oil of Helichrysum (HEO) possesses known anti-inflammatory properties, yet its therapeutic efficacy and underlying mechanisms in AD remain to be fully elucidated. This stu...

Yong-Qi Chen, Zhong-Ying Xu, Li-Ming Mao et al. · 0 citations
Open access Oct 2026

α-Boswellic acid alleviates atopic dermatitis via MME-mediated restoration of IL-18 BP/IL-18 axis homeostasis.

ObjectiveAtopic dermatitis (AD) involves complex immune dysregulation, with the IL-18 BP/IL-18 axis emerging as a critical yet underexplored regulator of pathological inflammation. While α-boswellic acid (α-BA) has shown therapeutic promise in AD, its role in regulating the IL-18 BP/IL-18 axis under the inflammatory mi...

Jian-Li Pan, Lu-Hao Wang, Rong-Rong Jing et al. · 0 citations
Oct 2026

Alnustone ameliorates atopic dermatitis by rebalancing TAp63/ΔNp63 to upregulate filaggrin and restore skin barrier function.

Atopic dermatitis (AD) is a chronic, pruritic, erythematous skin condition with skin barrier dysfunction, driven largely by filaggrin (FLG) deficiency; however, direct FLG-targeting therapeutics remains lacking. To identify novel natural products capable of enhancing FLG expression, we screened an in-house natural prod...

Chun-Zheng Wang, Ke Tang, Ying Guo · 0 citations
Oct 2026

Quercetin confers protection against psoriasis by inhibiting AKR1B10-mediated glycolytic reprogramming in keratinocytes.

The anti-psoriatic effect of quercetin has been observed. However, the involved mechanism remains poorly explored. Hence, the study investigated the therapeutic effects of quercetin against psoriasis and elucidated its underlying molecular mechanisms, with a focus on AKR1B10-mediated glycolytic reprogramming. An imiqui...

Hui-Qin Wang, Yan-Wen Liu, Yuan Ding et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.